Supreme Court Rules 7-2 for Monsanto, Effectively Ending Thousands of Roundup Cancer Lawsuits
In one of the most consequential product liability decisions in recent American legal history, the United States Supreme Court has ruled in favor of Bayer-owned former Monsanto Company, delivering a verdict expected to block thousands of pending lawsuits from individuals who claimed the popular weed killer Roundup caused them to develop cancer. The ruling, decided by a 7-2 majority, centers on the legal question of whether federal pesticide labeling regulations preempt state-level failure-to-warn claims — a distinction that carries enormous implications for consumers, corporations, and the future of pesticide litigation in the United States.
What Is the Case? Understanding Monsanto v Durnell
The specific case before the court, Monsanto v Durnell, focused on claims that the Monsanto Company failed to adequately warn users about the potential health risks associated with glyphosate, the active chemical ingredient in Roundup. Roundup is one of the most widely used herbicides in the world, applied on farms, residential lawns, golf courses, and public lands across the country for decades.
Plaintiffs in thousands of separate lawsuits have argued that long-term exposure to glyphosate contributed to their diagnosis of non-Hodgkin's lymphoma, a type of blood cancer. They maintained that Monsanto knew — or should have known — about these risks and that the company's warning labels were dangerously inadequate. The central legal issue, however, was not solely whether Roundup causes cancer, but whether federal law under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) overrides state-law requirements that companies provide additional safety warnings beyond those approved by the Environmental Protection Agency (EPA).
How the Court Voted and What the Justices Said
The Supreme Court's decision came down as a 7-2 ruling, with Justice Brett Kavanaugh authoring the majority opinion. The majority held that because the EPA had reviewed and approved Roundup's labeling — which does not include a cancer warning — state courts cannot require manufacturers to add warnings that go beyond what the federal agency has sanctioned. In other words, allowing state-level juries to mandate different or stronger warnings would create a patchwork of conflicting requirements that undermines the federal regulatory framework.
Justice Ketanji Brown Jackson wrote the dissenting opinion, joined by Justice Neil Gorsuch. The dissent argued that the ruling strips consumers of a critical legal avenue to seek accountability from corporations when federal regulatory approval may be insufficient to protect public health. Jackson's dissent emphasized that FIFRA was not designed to completely eliminate a manufacturer's responsibility to consumers under state tort law.
The unusual alignment — with Gorsuch joining the liberal Jackson in dissent — underscored how the legal question transcended typical ideological lines and turned instead on careful statutory interpretation.
What This Means for the Thousands of Pending Roundup Lawsuits
The practical impact of this ruling is sweeping. Tens of thousands of lawsuits were filed across the United States by individuals and families alleging that Roundup exposure led to cancer diagnoses. Bayer, which acquired Monsanto in 2018, had already paid out billions of dollars in settlements in prior Roundup cases — reaching agreements totaling roughly $10 billion in 2020 alone — while simultaneously appealing to have courts recognize federal preemption as a shield against further liability.
With the Supreme Court now affirming the federal preemption argument on failure-to-warn claims, legal experts expect the vast majority of remaining lawsuits to be dismissed or significantly weakened. Plaintiffs who built their cases primarily on the premise that Monsanto failed to warn them of cancer risks now face an extremely difficult path forward in federal court.
The Science Behind Glyphosate and Cancer Risk
The debate over whether glyphosate causes cancer has been fiercely contested in scientific and regulatory circles for years. In 2015, the International Agency for Research on Cancer (IARC), a division of the World Health Organization, classified glyphosate as "probably carcinogenic to humans." This classification became the foundation for many of the lawsuits against Monsanto.
However, the EPA has repeatedly reviewed the available science and maintained that glyphosate is "not likely to be carcinogenic to humans" when used as directed. The agency reaffirmed this position in its 2020 interim registration review decision. This regulatory disagreement between IARC and the EPA created the fault line around which the entire wave of Roundup litigation was built.
Broader Implications: Corporate Liability and Consumer Protections
Beyond Roundup specifically, this ruling sets a precedent with far-reaching consequences for how product liability law functions across many industries. If federal regulatory approval of a product's labeling is sufficient to shield manufacturers from state failure-to-warn claims, consumers lose one of their most powerful legal tools for seeking recourse when they believe a product harmed them.
Advocacy groups and consumer protection organizations have raised alarms that the decision could embolden other industries — including pharmaceuticals, food manufacturing, and chemicals — to rely on federal label approvals as a near-automatic defense against state court accountability.
Business groups and manufacturers, on the other hand, have welcomed the ruling as a necessary clarification that brings consistency and predictability to product liability law, preventing juries in individual states from effectively overriding expert federal regulatory determinations.
Environmental and public health lawyers argue the ruling highlights a deeper structural problem: when federal agencies like the EPA fail to incorporate the most current independent science into their assessments, the consequences for public health can be severe — and now, with this ruling, potentially irreversible in court.
What Happens Next?
For the plaintiffs and their families, many of whom are cancer survivors or are grieving loved ones lost to non-Hodgkin's lymphoma, the ruling is a significant setback. Their legal teams will likely explore whether any remaining claims — such as those grounded in negligent testing, fraud, or theories of liability not exclusively tied to failure-to-warn — can survive in light of the new precedent.
For Bayer, the ruling offers substantial financial relief and a measure of legal certainty that has eluded the company since it absorbed Monsanto's sprawling liability eight years ago. The company's stock responded positively to news of the decision, reflecting investor optimism that the ruling would put a definitive ceiling on Roundup-related exposure.
Congress could theoretically respond to the ruling by amending FIFRA to explicitly preserve state-law failure-to-warn claims, though prospects for such legislation remain uncertain given the current political landscape.
Key Takeaways from the Monsanto Supreme Court Ruling
The Supreme Court ruled 7-2 in Monsanto v Durnell, finding that EPA-approved pesticide labels under FIFRA preempt state failure-to-warn claims.
Justice Brett Kavanaugh wrote the majority opinion; Justice Ketanji Brown Jackson dissented, joined by Justice Neil Gorsuch.
The decision is expected to block tens of thousands of pending Roundup cancer lawsuits across the United States.
Glyphosate, Roundup's active ingredient, has been classified as a probable carcinogen by the WHO's IARC, but the EPA maintains it is not likely carcinogenic when used as directed.
The ruling has broad implications for product liability law, potentially limiting consumer recourse in cases where federal agencies have approved a product's labeling.
The Supreme Court's decision in Monsanto v Durnell will be studied by legal scholars, public health advocates, and corporate lawyers for years to come. It represents a pivotal moment in the long-running battle over Roundup — and a defining statement about where the boundary between federal oversight and consumer protection law now stands in the United States.